Evidence map›Paper›PMID 35682907›Full record

ArticleInternational journal of molecular sciences2022

Inhibitors of Mitochondrial Human Carbonic Anhydrases VA and VB as a Therapeutic Strategy against Paclitaxel-Induced Neuropathic Pain in Mice.

Laura Micheli, Lara Testai, Andrea Angeli, Donatello Carrino, Alessandra Pacini, Francesco Margiotta, Lorenzo Flori, Claudiu T Supuran, Vincenzo Calderone, Carla Ghelardini and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. The dual role of VEGF-A in a complex in vitro model of oxaliplatin-induced neurotoxicity: Pain-related and neuroprotective effects.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
  2. Review
  3. Review
  4. Review
  5. Progress of Section "Biochemistry" in 2022.International journal of molecular sciences · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Laura MicheliDepartment of Neuroscience, Psychology, Drug Research and Child Health, NEUROFARBA-Pharmacology and Toxicology Section, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy.ORCID 0000-0001-8834-5801
Lara TestaiDepartment of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.ORCID 0000-0003-2431-6248
Andrea AngeliDepartment of Neuroscience, Psychology, Drug Research and Child Health, Pharmaceutical and Nutraceutical Sciences Section, University of Florence, Via Ugo Schiff 6, 50019 Florence, Italy.ORCID 0000-0002-1470-7192
Donatello CarrinoDepartment of Experimental and Clinical Medicine, Anatomy and Histology Section, University of Florence, Largo Brambilla 3, 50134 Florence, Italy.
Alessandra PaciniDepartment of Experimental and Clinical Medicine, Anatomy and Histology Section, University of Florence, Largo Brambilla 3, 50134 Florence, Italy.ORCID 0000-0002-4098-7626
Francesco MargiottaDepartment of Neuroscience, Psychology, Drug Research and Child Health, NEUROFARBA-Pharmacology and Toxicology Section, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy.ORCID 0000-0002-4172-2478
Lorenzo FloriDepartment of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.
Claudiu T SupuranDepartment of Neuroscience, Psychology, Drug Research and Child Health, Pharmaceutical and Nutraceutical Sciences Section, University of Florence, Via Ugo Schiff 6, 50019 Florence, Italy.ORCID 0000-0003-4262-0323
Vincenzo CalderoneDepartment of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.
Carla GhelardiniDepartment of Neuroscience, Psychology, Drug Research and Child Health, NEUROFARBA-Pharmacology and Toxicology Section, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy.
Lorenzo Di Cesare MannelliDepartment of Neuroscience, Psychology, Drug Research and Child Health, NEUROFARBA-Pharmacology and Toxicology Section, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy.ORCID 0000-0001-8374-4432
University of Florence · ITUniversity of Pisa · IT

Funding

Italian Ministry of University and Research not availableNeuroDeRisk 821528University of Florence not available
6 · The paper itself

Abstract

Neuropathy development is a major dose-limiting side effect of anticancer treatments that significantly reduces patient's quality of life. The inadequate pharmacological approaches for neuropathic pain management warrant the identification of novel therapeutic targets. Mitochondrial dysfunctions that lead to reactive oxygen species (ROS) increase, cytosolic Ca

Indexed as

Carbonic AnhydrasesNeuralgiaAnimalsCarbonic Anhydrase InhibitorsHumansHyperalgesiaMicePaclitaxelQuality of LifeCarbonic Anhydrase InhibitorsCarbonic AnhydrasesPaclitaxelcarbonic anhydraseCA VA and VBglial cellsmitochondrianeuropathic painneuroprotectionTaxus brevifolia

Identifiers

PMID35682907
PMCPMC9181376
OpenAlexW4281668593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.